Cargando…

Targeted immune epitope prediction to HHLA2 and MAGEB5 protein variants as therapeutic approach to related viral diseases

BACKGROUND: Targeted immunotherapy is mostly associated with cancer treatment wherein designed molecules engage signaling pathways and mutant proteins critical to the survival of the cell. One of several genetic approaches is the use of in silico methods to develop immune epitopes targeting specific...

Descripción completa

Detalles Bibliográficos
Autores principales:	Achinko, Daniel A., Dormer, Anton, Narayanan, Mahesh, Norman, Elton F.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2021
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8316541/ https://www.ncbi.nlm.nih.gov/pubmed/34320928 http://dx.doi.org/10.1186/s12865-021-00440-w

Ejemplares similares

A Review of the Therapeutic Targeting of SCN9A and Nav1.7 for Pain Relief in Current Human Clinical Trials
por: Dormer, Anton, et al.
Publicado: (2023)

KIR3DL3-HHLA2 and TMIGD2-HHLA2 pathways: The dual role of HHLA2 in immune responses and its potential therapeutic approach for cancer immunotherapy
por: Li, Yang, et al.
Publicado: (2022)

Demethylation of CpG islands in the 5' upstream regions mediates the expression of the human testis-specific gene MAGEB16 and its mouse homolog Mageb16
por: Liu, Yunqiang, et al.
Publicado: (2014)

MAGEB2 is Activated by Promoter Demethylation in Head and Neck Squamous Cell Carcinoma
por: Pattani, Kavita M., et al.
Publicado: (2012)

Depletion of Mageb16 induces differentiation of pluripotent stem cells predominantly into mesodermal derivatives
por: Gaspar, John Antonydas, et al.
Publicado: (2017)

X-linked palindromic gene families 4930567H17Rik and Mageb5 are dispensable for male mouse fertility
por: Stark-Dykema, Evan R., et al.
Publicado: (2022)

ODF4, MAGEA3, and MAGEB4: Potential Biomarkers in Patients with Transitional Cell Carcinoma
por: Afsharpad, Mandana, et al.
Publicado: (2018)

Overexpression and Role of HHLA2, a Novel Immune Checkpoint, in Colorectal Cancer
por: Kula, Agnieszka, et al.
Publicado: (2023)

HHLA2 is a novel prognostic predictor and potential therapeutic target in malignant glioma
por: Qi, Yangzhi, et al.
Publicado: (2019)

HHLA2 is a novel prognostic predictor and potential therapeutic target in malignant glioma
por: Qi, Yangzhi, et al.
Publicado: (2022)

Regulation of HHLA2 expression in kidney cancer and myeloid cells
por: Shigemura, Tomonari, et al.
Publicado: (2023)

MAGEB2-Mediated Degradation of EGR1 Regulates the Proliferation and Apoptosis of Human Spermatogonial Stem Cell Lines
por: Zhao, Xueheng, et al.
Publicado: (2023)

Clinical Significance of the HHLA2 Protein in Hepatocellular Carcinoma and the Tumor Microenvironment
por: Luo, Min, et al.
Publicado: (2021)

HHLA2 Expression is Associated with Poor Survival in Patients with Hepatocellular Carcinoma
por: Xu, Yituo, et al.
Publicado: (2021)

Prognostic Significance of Potential Immune Checkpoint Member HHLA2 in Human Tumors: A Comprehensive Analysis
por: Wang, Ben, et al.
Publicado: (2019)

Comprehensive Analysis of HHLA2 as a Prognostic Biomarker and Its Association With Immune Infiltrates in Hepatocellular Carcinoma
por: Ding, Lin, et al.
Publicado: (2022)

HHLA2 in intrahepatic cholangiocarcinoma: an immune checkpoint with prognostic significance and wider expression compared with PD-L1
por: Jing, Chu-Yu, et al.
Publicado: (2019)

Clinical Significance of the HHLA2 Protein in Hepatocellular Carcinoma and the Tumor Microenvironment [Corrigendum]
Publicado: (2021)

HHLA2 predicts better survival and exhibits inhibited proliferation in epithelial ovarian cancer
por: Xu, Guocai, et al.
Publicado: (2021)

The combination of novel immune checkpoints HHLA2 and ICOSLG: A new system to predict survival and immune features in esophageal squamous cell carcinoma
por: Zhang, Chaoqi, et al.
Publicado: (2020)

Epitope length variants balance protective immune responses and viral escape in HIV-1 infection
por: Pymm, Phillip, et al.
Publicado: (2022)

Over-Expression and Prognostic Significance of HHLA2, a New Immune Checkpoint Molecule, in Human Clear Cell Renal Cell Carcinoma
por: Zhang, Zhen, et al.
Publicado: (2020)

HHLA2 is expressed in pancreatic and ampullary cancers and increased expression is associated with better post-surgical prognosis
por: Boor, Patrick P. C., et al.
Publicado: (2020)

Prognostic value of HHLA2 expression in solid tumors: A meta-analysis based on the Chinese population
por: Zhang, Chuanmeng, et al.
Publicado: (2021)

HHLA2 Used as a Potential Prognostic and Immunological Biomarker and Correlated with Tumor Microenvironment in Pan-Cancer
por: Yang, Zeng, et al.
Publicado: (2022)

Increased co-expression of stromal HHLA2 and fibroblast activation protein in upper tract urothelial carcinoma
por: Nishihara, Daisaku, et al.
Publicado: (2023)

Immunosuppression by Inflammation-Stimulated Amplification of Myeloid-Derived Suppressor Cells and Changes in Expression of Immune Checkpoint HHLA2 in Chronic Obstructive Pulmonary Disease
por: Xu, Lijuan, et al.
Publicado: (2023)

HHLA2, a member of the B7 family, is expressed in human osteosarcoma and is associated with metastases and worse survival
por: Koirala, Pratistha, et al.
Publicado: (2016)

Overexpression of HHLA2, a member of the B7 family, is associated with worse survival in human colorectal carcinoma
por: Zhu, Ziwen, et al.
Publicado: (2018)

Overexpression of HHLA2 in human clear cell renal cell carcinoma is significantly associated with poor survival of the patients
por: Chen, Lujun, et al.
Publicado: (2019)

Coexpression of HHLA2 and PD-L1 on Tumor Cells Independently Predicts the Survival of Spinal Chordoma Patients
por: Xia, Chao, et al.
Publicado: (2022)

HHLA2 predicts improved prognosis of anti-PD-1/PD-L1 immunotherapy in patients with melanoma
por: Huang, Fu-xue, et al.
Publicado: (2022)

HHLA2 promotes tumor progression by long non-coding RNA H19 in human gallbladder cancer
por: Zhang, Yizhou, et al.
Publicado: (2022)

X-Linked Adrenal Hypoplasia Congenita in a Boy due to a Novel Deletion of the Entire NR0B1 (DAX1) and MAGEB1–4 Genes
por: Rojek, Aleksandra, et al.
Publicado: (2016)

B7-H7 (HHLA2) inhibits T-cell activation and proliferation in the presence of TCR and CD28 signaling
por: Rieder, Sadiye Amcaoglu, et al.
Publicado: (2020)

Corrigendum: Coexpression of HHLA2 and PD-L1 on tumor cells independently predicts the survival of spinal chordoma patients
por: Xia, Chao, et al.
Publicado: (2023)

Complexity of Viral Epitope Surfaces as Evasive Targets for Vaccines and Therapeutic Antibodies
por: Miller, Nathaniel L., et al.
Publicado: (2022)

HHLA2 and PD-L1 co-expression predicts poor prognosis in patients with clear cell renal cell carcinoma
por: Zhou, Qiang-Hua, et al.
Publicado: (2020)

HHLA2 deficiency inhibits non‐small cell lung cancer progression and THP‐1 macrophage M2 polarization
por: Sun, Wenjie, et al.
Publicado: (2021)

Eliciting unnatural immune responses by activating cryptic epitopes in viral antigens
por: Lee, Young Jae, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_d1lp2djhofse4nhvvrs7v94qc7